Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 262

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Open access
Armand, Philippe, Rodig, Scott, Melnichenko, Vladimir, Thieblemont, Catherine, Bouabdallah, Kamal, Tumyan, Gayane, Özcan, Muhit, Portino, Sergio, Fogliatto, Laura, Caballero, Maria D., Walewski, Jan, Gulbas, Zafer, Ribrag, Vincent, Christian, Beth, Perini, Guilherme Fleury, Salles, Gilles, Svoboda, Jakub, Zain, Jasmine, Patel, Sanjay, Chen, Pei-Hsuan, Ligon, Azra H., Ouyang, Jing, Neuberg, Donna, Redd, Robert, Chatterjee, Arkendu, Balakumaran, Arun, Orlowski, Robert, Shipp, Margaret, Zinzani, Pier Luigi · 2019 · Journal of Clinical Oncology

Abstract

PURPOSE: Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands (PD-L1), it is hypothesized to be susceptible to PD-1 blockade. METHODS: In the phase IB KEYNOTE-013 (ClinicalTrials.gov identifier: NCT01953692 ) and phase II KEYNOTE-170 (ClinicalTrials.gov identifier: NCT02576990 ) studies, adults with rrPMBCL received pembrolizumab for up to 2 years or until disease progression or unacceptable toxicity. The primary end points were safety and objective response rate in KEYNOTE-013 and objective response rate in KEYNOTE-170. Secondary end points included duration of response, progression-free survival, overall survival, and safety. Exploratory end points included association between biomarkers and pembrolizumab activity. RESULTS: The objective response rate was 48% (7 complete responses; 33%) among 21 patients in KEYNOTE-013 and 45% (7 complete responses; 13%) among 53 patients in KEYNOTE-170. After a median follow-up time of 29.1 months in KEYNOTE-013 and 12.5 months in KEYNOTE-170, the median duration of response was not reached in either study. No patient with complete response experienced progression, including 2 patients with complete response for at least 1 year off therapy. Treatment-related adverse events occurred in 24% of patients in KEYNOTE-013 and 23% of patients in KEYNOTE-170. There were no treatment-related deaths. Among 42 evaluable patients, the magnitude of the 9p24 gene abnormality was associated with PD-L1 expression, which was itself significantly associated with progression-free survival. CONCLUSION: Pembrolizumab is associated with high response rate, durable activity, and a manageable safety profile in patients with rrPMBCL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.01389

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 262

Metadata

Authors
Armand, P., Rodig, S., Melnichenko, V., Thieblemont, C., Bouabdallah, K., Tumyan, G., Özcan, M., Portino, S., Fogliatto, L., Caballero, M. D., Walewski, J., Gulbas, Z., Ribrag, V., Christian, B., Perini, G. F., Salles, G., Svoboda, J., Zain, J., Patel, S., Chen, P.-H., Ligon, A. H., Ouyang, J., Neuberg, D., Redd, R., Chatterjee, A., Balakumaran, A., Orlowski, R., Shipp, M., & Zinzani, P. L.
Venue
Journal of Clinical Oncology
Published
2019-12-01
Volume
37
Issue
34
Pages
3291-3299
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2979952645
Cited by
262
References
16
FWCI
22.69
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. https://app.cochat.ai/papers/10.1200/jco.19.01389
The paper
Armand, P., Rodig, S., Melnichenko, V., Thieblemont, C., Bouabdallah, K., Tumyan, G., Özcan, M., Portino, S., Fogliatto, L., Caballero, M. D., Walewski, J., Gulbas, Z., Ribrag, V., Christian, B., Perini, G. F., Salles, G., Svoboda, J., Zain, J., Patel, S., . . . Zinzani, P. L. (2019). Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.01389

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.